Vigil Neuroscience Inc. - VIGL Net earnings per share growth forecast for next year
What are the prospects for Vigil Neuroscience (VIGL) given the development of the drug VG-3927 to combat brain degeneration? A virtual production model utilizing external contractors in Europe and the US provides the answer. The company's EPS forecast trends for next year demonstrate market expectations, where the 11.40 level captures the current state. Business development relies on strategic alliances with experts in the field of neuroimmunology.
Vigil Neuro - analytical breakdowns and key metrics (VIGL)
- stock quotes and analyst forecast:
- issuer market value details:
- company book value details:
- debt obligations and liquidity statistics:
Debt to Equity Vigil Neuroscience|VIGL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Vigil Neuroscience Inc.|VIGL - Company Cumulative Debt|Debt to Book Capitalization Ratio Vigil Neuroscience, Inc.|VIGL - Long-Term Debt Volume|Company Short-Term Debts Vigil Neuroscience|Quick Ratio vigilneuro.com
- earnings and valuation multiples information:
VIGL - Net Financial Result|Projected Future Earnings Vigil Neuroscience|VIGL - Market Cap to Earnings|Future Price to Earnings Vigil Neuroscience, Inc.|VIGL - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Vigil Neuro|VIGL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Vigil Neuroscience|VIGL - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months vigilneuro.com|VIGL - Earnings per share growth in current year|Earnings growth forecast for next year Vigil Neuroscience
- total revenue and sales volume data:
Fundamental company analysis:VIGL, Vigil Neuro
The investment attractiveness of Vigil Neuroscience (VIGL) is based on the success of clinical developments within strict FDA regulations. This indicator captures the market consensus on profit growth rates for the coming period, excluding subjective market volatility. By analyzing the EPS trend benchmark for Vigil Neuroscience (VIGL) for the next year, investors assess the business's fundamental resilience to regulatory risks and the capitalization potential of its biopharmaceutical assets.
Competitor analysis
Net earnings per share growth forecast for next year Biogen|Expected earnings per share growth for next year neurocrine.com (NBIX)|Net earnings per share growth forecast for next year Regencell Bioscience Holdings Limited (RGC)|AXSM (Axsome Therapeutics Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals Inc. ACAD|Expected earnings per share trend next year XENE|Viking Therapeutics - Earnings growth forecast for next year|Expected earnings per share trend next year SUPN (supernus.com)|Catalyst Pharmaceuticals (CPRX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Denali (DNLI)|Net earnings per share growth forecast for next year harmonybiosciences.com|BHVN (Biohaven Pharmaceutical) - Projected earnings per share increase next year|Net earnings per share growth forecast for next year amylyx.com (AMLX)|TRVI: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year Praxis Precision Medicines Inc PRAX|Consensus forecast of earnings per share growth for next year Anavex Life Sciences Corp. (AVXL)|CeriBell EEG - Earnings growth forecast for next year|Expected net earnings per share growth next year Prothena Corp|ALEC: Earnings growth forecast for next year|Projected earnings per share growth rate for next year ANNX|OMER (Omeros) - Earnings growth forecast for next year|NGNE - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year AC Immune Corp (ACIU)|Projected earnings per share increase next year VYGR|Earnings growth forecast for next year NMRA (neumoratx.com)|SCLX - Expected earnings per share growth for next year|tevogen.com - Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Alpha Cognition Inc. (ACOG)|CGTX: Earnings growth forecast for next year|IKT - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year SAVA|Expected earnings per share growth for next year Assertio (ASRT)|Expected earnings per share growth for next year COYA (Coya)|Net earnings per share growth forecast for next year VTGN (VistaGen Therapeutics Inc)|Net earnings per share growth forecast for next year Ovid Therapeutics OVID|Earnings growth forecast for next year Acumen Pharma ABOS|CervoMed, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year ATHE (alteritytherapeutics.com)|CLNN (Clene Nanomedicine) - Expected earnings per share growth for next year|Expected net earnings per share growth next year PepGen Corp (PEPG)|Net earnings per share growth forecast for next year Jupiter Neurosciences Inc|Expected net earnings per share growth next year Relmada Therapeutics RLMD|Net earnings per share growth forecast for next year Annovis Bio (ANVS)|GRCE - Expected net earnings per share growth next year|Earnings growth forecast for next year AIFF (Firefly Neuroscience, Inc)|Klotho Neurosciences Inc (KLTO) - Expected net earnings per share growth next year|NeuroSense Therapeutics, Ltd. - Earnings growth forecast for next year|RVPH - Earnings growth forecast for next year|MetaVia Inc (MTVA) - Net earnings per share growth forecast for next year|NRXS - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year heliusmedical.com|PASG - Net earnings per one share growth forecast for next year|Net earnings per share growth forecast for next year Neuphoria (NEUP)|Consensus forecast of earnings per share growth for next year Minerva|Earnings growth forecast for next year ATHA (Athira Pharma Corp)|Expected earnings per share trend next year ADXN|Alzamend - Earnings growth forecast for next year|Cyclerion Therapeutics, Inc. (CYCN) - Expected earnings per share growth for next year|protagenic.com (PTIX) - Net earnings per share growth forecast for next year|KTTA: Projected earnings per share increase next year|CRGT (cortigent.com) - Earnings growth forecast for next year|ATXI (Avenue Therapeutics) - Projected earnings per share increase next year|Earnings growth forecast for next year BCLI|Projected earnings per share increase next year CARA|Net earnings per share growth forecast for next year chromocell.com CHRO|Earnings growth forecast for next year Eliem Therapeutics ELYM|ITCI: Expected earnings per share growth for next year|LBPH: Net earnings per share growth forecast for next year|MRNS (Marinus Pharmaceuticals, Inc.) - Expected earnings per share growth for next year|NKGen - Expected earnings per share trend next year|Net earnings per share growth forecast for next year NeuroBo Pharmaceuticals, Inc.|Earnings growth forecast for next year Sage Therapeutics Inc|Earnings growth forecast for next year SNPX|TRVN - Expected net earnings per share growth next year|Anew Medical Inc. - Expected earnings per share growth for next year|CERE (Cerevel Therapeutics, Inc.) - Net earnings per share change forecast for next year
